CalciMedica Inc. (CALC), a clinical-stage biopharmaceutical company, is drawing attention as it develops novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses.
Shares closed Thursday at $3.16, up 0.13 percent, within a day's range of $3.16 to $3.28. The company's 52-week range spans $1.42 to $4.26, with an intraday market capitalization of $45.5 million. Trading volume of 14,098 shares was below the average of 50,179, reflecting a relatively quiet session despite the company's active clinical and corporate updates.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.